For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Treatment Group: Radiesse (+) Injectable Implant | Participants received Radiesse+Lidocaine Injectable Implant up to 3.0cc volume, once within the jawline region of anterior to posterior boundaries (from the mentum to the earlobe) and superior to inferior boundaries (from the lower cheek to the lower body of the jawline). | 0 | None | 0 | 19 | 19 | 19 | View |
| Control Group: Untreated | Participants did not receive jawline treatment. | 0 | None | 0 | 10 | 0 | 10 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Injection site bruising | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (18.1) | View |
| Injection site swelling | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (18.1) | View |
| Nodule | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (18.1) | View |
| Pain | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (18.1) | View |
| Erythema | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA (18.1) | View |